Physician profile
Peter Mehta
NPI 1386092591
$1,198.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.14 · 2020: $219 · 2021: $955.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $224.92 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $135.44 | 2021 | |
| Sunovion Pharmaceuticals INC. | $100.12 | 2021 | |
| Vanda Pharmaceuticals INC. | $82.56 | 2020-2021 | |
| Lundbeck LLC | $82.17 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.69 | 2020-2021 | |
| Bausch Health US, LLC | $44.11 | 2021 | |
| Eisai INC. | $41.76 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.35 | 2021 | |
| Neos Therapeutics, Lp | $30.86 | 2020-2021 | |
| Allergan, INC. | $24.14 | 2019 | |
| Tris Pharma INC | $19.07 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.